Synbiotic vs placebo
Withdrawals due to adverse events · children with chronic constipation without a physical explanation
1 finding from 1 review
- no estimate extracted1 study · 155 participantsGRADE not reported
Findings
What do systematic reviews say?
637 questions · 674 findings · 79 reviews · Gut
No studies found 116 · 17.2%GRADE not reported 14 · 2.1%Very low 133 · 19.7%Low 225 · 33.4%Moderate 145 · 21.5%High 41 · 6.1%
Synbiotic vs placebo
Serious adverse events · children with chronic constipation without a physical explanation
1 finding from 1 review
- no estimate extracted1 study · 155 participantsGRADE not reported
Probiotics vs placebo
Global improvement or treatment success, as defined by primary study · children with chronic constipation without a physical explanation
Probiotic may leads to higher global improvement/treatment success as defined by primary study compared with placebo (low certainty).
1 finding from 1 review
- RR 1.294 studies · 313 participantsLow
Probiotics vs placebo
Withdrawals due to adverse events · children with chronic constipation without a physical explanation
Probiotic showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 0.64 [0.21, 1.95]5 studies · 357 participantsLow
Probiotics vs placebo
Serious adverse events · children with chronic constipation without a physical explanation
1 finding from 1 review
- no estimate extracted4 studies · 198 participantsGRADE not reported
Antidepressants vs placebo
Treatment success (caries lesion arrest or restoration survival) · children (4 to 18 years) with functional abdominal pain disorders
Antidepressant showed no clear difference in treatment success compared with placebo (low certainty).
1 finding from 1 review
- Antidepressants for functional abdominal pain disorders in children and adolescents 2021 · Cochrane Headline outcomes onlyRR 1.17 [0.87, 1.56]2 studies · 205 participantsLow
Antidepressants vs placebo
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
Antidepressant showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Antidepressants for functional abdominal pain disorders in children and adolescents 2021 · Cochrane Headline outcomes onlyRR 3.17 [0.65, 15.33]3 studies · 238 participantsLow
Oral ferric maltol vs oral placebo
Serious adverse events ‐ mild disease to quiescent (up to 52 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
- Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyRR 1 [0.15, 6.88]1 study · 128 participantsVery low
IM erythropoietin vs oral placebo
Number of responders · IBD patients
It is very uncertain whether IM erythropoietin changes number of responders ‐ active disease (12 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
- Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyRR 3.5 [1.44, 8.48]1 study · 34 participantsVery low
IM erythropoietin vs oral placebo
Serious adverse events · IBD patients
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
IM erythropoietin + IV iron sucrose vs IV iron sucrose + IM placebo
Number of responders ‐ disease activity not stated (12 weeks) · IBD patients
IM erythropoietin + IV iron sucrose showed no clear difference in number of responders ‐ disease activity not stated (12 weeks) compared with IV iron sucrose + IM placebo (low certainty).
1 finding from 1 review
- Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyRR 1.2 [0.9, 1.61]1 study · 40 participantsLow
IM erythropoietin + IV iron sucrose vs IV iron sucrose + IM placebo
Serious adverse events ‐ disease activity not stated (12 weeks) · IBD patients
1 finding from 1 review
- Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 40 participantsVery low
Oral ferric maltol vs oral placebo
Number of responders · IBD patients
It is very uncertain whether oral ferric maltol changes number of responders ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
- Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyRR 73 [4.58, 1164.36]1 study · 128 participantsVery low
Enteric‐release glyceryl trinitrate vs placebo
Treatment success as defined by the authors · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Enteric‐release glyceryl trinitrate vs placebo
Abdominal pain frequency or change in frequency · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Enteric‐release glyceryl trinitrate vs placebo
Abdominal pain intensity or change in intensity · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Enteric‐release glyceryl trinitrate vs placebo
Withdrawals due to adverse events · people with Crohn's disease
It is very uncertain whether enteric‐release glyceryl trinitrate changes withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyRR 3.18 [0.94, 10.76]1 study · 70 participantsVery low
Oral 5‐ASA vs placebo
Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA leads to lower failure to induce complete global or clinical remission compared with placebo (high certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes onlyRR 0.86 [0.82, 0.89]11 studies · 2387 participantsHigh
Oral 5‐ASA vs placebo
Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower failure to induce global or clinical improvement compared with placebo (moderate certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes onlyRR 0.68 [0.61, 0.75]14 studies · 2256 participantsModerate
Oral 5‐ASA vs placebo
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower failure to induce endoscopic remission compared with placebo (moderate certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes onlyRR 0.77 [0.67, 0.89]4 studies · 1154 participantsModerate